Supernus Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Supernus Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Supernus Pharmaceuticals Inc recorded a cumulative net loss of $-110 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -7.53%.

However, within the Healthcare sector 277 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 2765, from total ROA ranking in the first quarter of 2026 at 3277.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	3.69 %	11.39 %	9.12 %	5.24 %	4.67 %
Y / Y Net Income Change	-	-	-	-	12.97 %
Net Income (TTM) in million	-110	-29	-39	-19	64
Return On Assets (TTM)	-7.53 %	-2.01 %	-2.74 %	-1.39 %	4.75 %
SUPN's Total Ranking	# 2765	# 3277	# 2757	# 1232	# 1266
Total Assets (TTM) in million	1,428	1,501	1,493	1,413	1,377
Seq. Total Assets Change	-4.84 %	0.53 %	5.65 %	2.6 %	2.22 %
Seq. Net Income Change	-	-	-	-	-

SUPN's 5 Years Annual ROA >> Back to SUPN Management Effectiveness >> Compare SUPN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 96
Sector	# 278
Overall	# 3077

Return On Assets Statistics
High	Average	Low
37.78 %	-0.03 %	-78.23 %
(Sep 30 2016)		(Jun 30 2013)

Financial Statements
Supernus Pharmaceuticals Inc 's Assets	$ 1,428 million	SUPN's Balance sheet
Supernus Pharmaceuticals Inc 's Income	$ -58 million	Quarterly SUPN's Income Statement
SUPN's Income by Division		See SUPN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	6.18 %	-19.69 %	0.85 %	12.3 %	29.63 %
Total Assets in million	1,453	1,368	1,704	1,689	1,504
Y / Y Net Income Change	-	21.67 %	13.64 %	-57.92 %	12.29 %
Net Income in million	-39	74	61	53	127
Annual Return On Assets	-2.65 %	5.4 %	3.56 %	3.16 %	8.44 %

SUPN's 5 Years Annual ROA >> Back to SUPN Management Effectiveness >> Compare SUPN ROA to its Competitors

More Return On Assets Ratios
SUPN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SUPN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SUPN's Competitors
Subscribers only: Roa for Supernus Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for SUPN's Customers

You may also want to know
SUPN's Roi	SUPN's Inventory Turnover Ratio	SUPN's Growth Rates	SUPN's Dividend Comparisons
	SUPN's Profitability Ratios	SUPN's Asset Turnover Ratio	SUPN's Dividend Growth
SUPN's Roe	SUPN's Valuation Ratios	SUPN's Financial Strength Ratios	SUPN's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-13T23:36:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.